JP2023502276A5 - - Google Patents

Info

Publication number
JP2023502276A5
JP2023502276A5 JP2022529715A JP2022529715A JP2023502276A5 JP 2023502276 A5 JP2023502276 A5 JP 2023502276A5 JP 2022529715 A JP2022529715 A JP 2022529715A JP 2022529715 A JP2022529715 A JP 2022529715A JP 2023502276 A5 JP2023502276 A5 JP 2023502276A5
Authority
JP
Japan
Prior art keywords
vaccine
formula
agent according
administered
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502276A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/061594 external-priority patent/WO2021102320A1/en
Publication of JP2023502276A publication Critical patent/JP2023502276A/ja
Publication of JP2023502276A5 publication Critical patent/JP2023502276A5/ja
Priority to JP2025178576A priority Critical patent/JP2026016535A/ja
Pending legal-status Critical Current

Links

JP2022529715A 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法 Pending JP2023502276A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025178576A JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025178576A Division JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Publications (2)

Publication Number Publication Date
JP2023502276A JP2023502276A (ja) 2023-01-23
JP2023502276A5 true JP2023502276A5 (OSRAM) 2023-11-29

Family

ID=75980043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022529715A Pending JP2023502276A (ja) 2019-11-22 2020-11-20 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025178576A Pending JP2026016535A (ja) 2019-11-22 2025-10-23 Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法

Country Status (11)

Country Link
US (1) US20230053458A1 (OSRAM)
EP (1) EP4061411A4 (OSRAM)
JP (2) JP2023502276A (OSRAM)
KR (1) KR20220107001A (OSRAM)
CN (1) CN114845731A (OSRAM)
AU (1) AU2020386971A1 (OSRAM)
BR (1) BR112022009924A2 (OSRAM)
CA (1) CA3162238A1 (OSRAM)
IL (1) IL293091A (OSRAM)
WO (1) WO2021102320A1 (OSRAM)
ZA (1) ZA202205546B (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220079534A (ko) * 2019-08-27 2022-06-13 알로펙스, 인크. 항미생물 백신 조성물
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
US20260015434A1 (en) * 2022-03-11 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103084A2 (en) * 2004-04-21 2005-11-03 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
NZ591103A (en) * 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
EP2847216A1 (en) * 2012-05-07 2015-03-18 Sanofi Methods for preventing biofilm formation
JP2015517496A (ja) * 2012-05-07 2015-06-22 サノフイ バイオフィルム形成を防止する方法
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Similar Documents

Publication Publication Date Title
ES2275499T3 (es) Vacuna contra streptococcus pneumoniae.
CN1154509C (zh) 含有混合载体的多价疫苗组合物
US8604184B2 (en) Chemically programmable immunity
ES2321892T3 (es) Composiciones de beta-glucanos e inmunoglobulinas especificas.
TW200914042A (en) Vaccine
JP2012017342A5 (OSRAM)
WO2020259076A1 (zh) 一种糖缀合物及其用途
JP2021001182A5 (OSRAM)
Xu et al. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein
JP2009514840A5 (OSRAM)
Pajon et al. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice
Merli et al. Management of vaccinations in patients with non‐Hodgkin lymphoma
ES2366735B1 (es) Vacuna frente a acinetobacter baumannii.
JP2021066727A5 (OSRAM)
WO2023025002A1 (zh) 一种肺炎球菌结合疫苗组合物
CN101130071B (zh) 疫苗
Akter et al. Glycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers
WO2023025003A1 (zh) 一种肺炎球菌结合疫苗制备方法
WO2013027063A1 (en) Chemically programmable immunity
Simoneaux IDWeek 2014, Philadelphia, Pennsylvania, USA, October 7-12, 2014
Pichichero The new meningococcal conjugate vaccine: A profile of its safety, efficacy, and indications for use
US20150079129A1 (en) Vaccine
MXPA01009455A (en) Vaccine
HK1106137A (en) Vaccine against streptococcus pneumoniae
TW201008578A (en) Vaccine composition